SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-23-018705
Filing Date
2023-11-13
Accepted
2023-11-13 09:00:14
Documents
15
Period of Report
2023-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aeon-20231113x8k.htm   iXBRL 8-K 39161
2 EX-99.1 aeon-20231113xex99d1.htm EX-99.1 321221
3 GRAPHIC aeon-20231113xex99d1001.jpg GRAPHIC 4104
  Complete submission text file 0001558370-23-018705.txt   544401

Data Files

Seq Description Document Type Size
4 EX-101.SCH aeon-20231113.xsd EX-101.SCH 3953
5 EX-101.DEF aeon-20231113_def.xml EX-101.DEF 14408
6 EX-101.LAB aeon-20231113_lab.xml EX-101.LAB 20460
7 EX-101.PRE aeon-20231113_pre.xml EX-101.PRE 14380
9 EXTRACTED XBRL INSTANCE DOCUMENT aeon-20231113x8k_htm.xml XML 7237
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

IRS No.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40021 | Film No.: 231395584
SIC: 2834 Pharmaceutical Preparations